We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Valeant Pharmaceuticals has announced the publication in Neurology of Phase II data on retigabine, a first-in-class neuronal potassium channel opener being developed as an adjunctive treatment for partial-onset seizures in patients with refractory epilepsy.
Coley Pharmaceutical has announced that Pfizer has completed target patient enrollment in two pivotal Phase III clinical trials of the Toll-like receptor 9 (TLR9) agonist drug candidate, PF-3512676, for the treatment of advanced, non-small-cell lung cancer (NSCLC).
Cleveland BioLabs has announced the results of its study of Protectan CBLB502's efficacy as a mitigator of radiation-induced
gastrointestinal (GI) and hematopoietic injury in nonhuman primates.
Ambit Biosciences announced that the first patients have been dosed in its Phase I clinical trial to evaluate AC220 in the treatment of acute myeloid leukemia (AML).
Pharmacopeia has announced positive results from the initial Phase I clinical trial of PS433540, the company's lead internal product candidate for the treatment of hypertension and diabetic nephropathy.
Threshold Pharmaceuticals has begun patient enrollment in a Phase II clinical trial evaluating the efficacy and safety of glufosfamide in patients with previously treated, advanced, soft-tissue sarcoma.
Immtech Pharmaceuticals has begun a Phase IIb clinical trial of its oral drug candidate pafuramidine maleate for treating uncomplicated malaria caused by Plasmodium falciparum.
EpiCept has initiated two Phase IIb trials with EpiCept NP-1, a topical analgesic cream for the long-term relief from the pain of peripheral neuropathies.